Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09GLS
|
|||
| Former ID |
DCL000412
|
|||
| Drug Name |
GSK1614235
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
GSK
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 1 (SGLT1) | Target Info | Blocker | [2] |
| KEGG Pathway | Carbohydrate digestion and absorption | |||
| Bile secretion | ||||
| Mineral absorption | ||||
| Pathwhiz Pathway | Lactose Degradation | |||
| Trehalose Degradation | ||||
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| Metabolism of carbohydrates | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01607385) A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.